UY33229A - Derivados de piridina tricíclicos, medicamentos que contienen tales compuestos, su uso y proceso pa ra su preparación - Google Patents

Derivados de piridina tricíclicos, medicamentos que contienen tales compuestos, su uso y proceso pa ra su preparación

Info

Publication number
UY33229A
UY33229A UY33229A UY33229A UY33229A UY 33229 A UY33229 A UY 33229A UY 33229 A UY33229 A UY 33229A UY 33229 A UY33229 A UY 33229A UY 33229 A UY33229 A UY 33229A
Authority
UY
Uruguay
Prior art keywords
compounds
preparation
pyridine derivatives
medicines containing
tricyclic pyridine
Prior art date
Application number
UY33229A
Other languages
English (en)
Inventor
Trieselmann Thomas
Dieter Wolfgang Hamprecht
Wagner Holger
Berta Daniela
Fuchs Klaus
Giovannini Riccardo
Konetzki Ingo
Streicher Ruediger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY33229A publication Critical patent/UY33229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Abstract

La presente invención se refiere a compuestos derivados de 1,3,6,7,8,9-hexahidro-furo[3,4-c]quinolina de fórmula I en la que las variables R1-R8 se definen como en la descripción, que poseen actividad farmacológica valiosa. Particularmente, los compuestos son inhibidores de la proteína de transferencia de éster de colesterol (CETP) y, por lo tanto, son adecuados para el tratamiento y prevención de enfermedades que pueden influenciarse por la inhibición de esta enzima.
UY33229A 2010-02-19 2011-02-17 Derivados de piridina tricíclicos, medicamentos que contienen tales compuestos, su uso y proceso pa ra su preparación UY33229A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10154086 2010-02-19

Publications (1)

Publication Number Publication Date
UY33229A true UY33229A (es) 2011-09-30

Family

ID=43877277

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33229A UY33229A (es) 2010-02-19 2011-02-17 Derivados de piridina tricíclicos, medicamentos que contienen tales compuestos, su uso y proceso pa ra su preparación

Country Status (22)

Country Link
US (2) US9029544B2 (es)
EP (1) EP2536733B1 (es)
JP (1) JP5780528B2 (es)
KR (1) KR20130000379A (es)
CN (1) CN102869667A (es)
AP (1) AP2012006390A0 (es)
AR (1) AR080228A1 (es)
AU (1) AU2011217206A1 (es)
BR (1) BR112012020591A2 (es)
CA (1) CA2790643A1 (es)
CL (1) CL2012002035A1 (es)
CO (1) CO6592112A2 (es)
EA (1) EA201201160A1 (es)
EC (1) ECSP12012157A (es)
MA (1) MA34007B1 (es)
MX (1) MX2012009149A (es)
PE (1) PE20121743A1 (es)
SG (1) SG183321A1 (es)
TN (1) TN2012000418A1 (es)
TW (1) TW201139445A (es)
UY (1) UY33229A (es)
WO (1) WO2011101424A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109549A1 (en) * 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
CA2790643A1 (en) 2010-02-19 2011-08-25 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
JP2014506887A (ja) * 2011-02-17 2014-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用およびそれらの調製のためのプロセス
WO2013024130A1 (en) * 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US20130210851A1 (en) * 2011-08-18 2013-08-15 Boehringer Ingelheim International Gmbh Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
CN103866646B (zh) * 2014-03-21 2015-10-28 湖南中烟工业有限责任公司 一种生产无酮转移卡纸的工艺
CN103882766B (zh) * 2014-03-21 2015-10-28 湖南中烟工业有限责任公司 一种除去包装卡纸中酮类物质的除酮添加剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798619A (en) 1980-06-02 1989-01-17 American Cyanamid Co. 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents
US4475407A (en) 1982-12-27 1984-10-09 Brunswick Corporation Temperature compensated flow sensor
CH664578A5 (de) * 1985-01-15 1988-03-15 Ciba Geigy Ag Ringsubstituierte 4-azaphthalide.
KR900701792A (ko) 1988-08-16 1990-12-04 로버어트 에이 아미테이지 Acat 효소를 차단하는데 효과적인 이가 리간드
TR199800531T1 (xx) 1995-09-29 1998-06-22 Glaxo Wellcome Spa NMDA antagonistleri olarak tetrahidrokinolinler.
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
JP2001514254A (ja) 1997-09-04 2001-09-11 ビーエーエスエフ アクチェンゲゼルシャフト 新規カルボン酸誘導体、その製造及び混合ｅｔａ／ｅｔｂエンドセリン受容体拮抗薬としてのその使用
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE69925612T2 (de) 1998-09-25 2006-03-16 Monsanto Co., Chicago (r)-chirale halogenierte 1-substituierte amino-(n+1)-alkanolen für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6677341B2 (en) 1999-09-23 2004-01-13 Pharmacia Corporation (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US6451823B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10238243A1 (de) * 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1737811B1 (en) 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
EP1828137B1 (de) 2004-12-18 2012-04-25 Bayer Pharma Aktiengesellschaft 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
EP1828136A1 (de) 2004-12-18 2007-09-05 Bayer HealthCare AG (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren
DE102004060997A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Chemische Verbindung und ihre Verwendung
JP2008201760A (ja) 2007-02-22 2008-09-04 Tokyo Univ Of Agriculture & Technology 光学活性スピロ化合物及びその製造方法
WO2009109549A1 (en) 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
CA2790643A1 (en) 2010-02-19 2011-08-25 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
JP2014506887A (ja) * 2011-02-17 2014-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用およびそれらの調製のためのプロセス
WO2013024130A1 (en) 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US20130210851A1 (en) 2011-08-18 2013-08-15 Boehringer Ingelheim International Gmbh Crystalline forms of a hexahydrofuro[3,4-c]quinoline derivative

Also Published As

Publication number Publication date
AU2011217206A1 (en) 2012-08-02
US20120053197A1 (en) 2012-03-01
EA201201160A1 (ru) 2013-04-30
SG183321A1 (en) 2012-09-27
TW201139445A (en) 2011-11-16
JP2013519709A (ja) 2013-05-30
US20120046304A1 (en) 2012-02-23
BR112012020591A2 (pt) 2017-10-10
CA2790643A1 (en) 2011-08-25
PE20121743A1 (es) 2012-12-22
WO2011101424A1 (en) 2011-08-25
CL2012002035A1 (es) 2013-02-01
JP5780528B2 (ja) 2015-09-16
AR080228A1 (es) 2012-03-21
MX2012009149A (es) 2012-09-28
CN102869667A (zh) 2013-01-09
EP2536733B1 (en) 2014-11-26
KR20130000379A (ko) 2013-01-02
US9029544B2 (en) 2015-05-12
EP2536733A1 (en) 2012-12-26
ECSP12012157A (es) 2012-10-30
TN2012000418A1 (en) 2014-01-30
MA34007B1 (fr) 2013-02-01
CO6592112A2 (es) 2013-01-02
AP2012006390A0 (en) 2012-08-31

Similar Documents

Publication Publication Date Title
UY33229A (es) Derivados de piridina tricíclicos, medicamentos que contienen tales compuestos, su uso y proceso pa ra su preparación
ECSP12012230A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
CR20130371A (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
CO6531468A2 (es) Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
BR112013000275A2 (pt) derivados de tetraidro-pirido-pirimidina
BR112012012617B8 (pt) processo para a produção de metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato
CR20120529A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
ECSP12012111A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
BR112015005168A2 (pt) Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
IN2015DN01547A (es)
CO6602133A2 (es) Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
UY33766A (es) COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
MX360856B (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con homopiperidinilo antibacterianas.
IN2014DN08551A (es)
BR112018004347A2 (pt) derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida
BR112014030507A2 (pt) compostos tricíclicos como inibidores de kat ii
MY164138A (en) Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191216